Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART

HIV Medicine

Volumn 10, Issue 10, 2009, Pages 657-660

  Taiwo, B O ^a   Li, X ^b   Palella, F ^a   Jacobson, L P ^b   Margolick, J B ^b   Detels, R ^c   Rinaldo, C R ^d   Phair, J P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

AIDS; CD4 cell count; Death; Viral load

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70449356789     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00739.x     Document Type: Article

References (15)

1. Benveniste O, Flahault A, Rollot F. Mechanisms involved in the low-level regeneration of CD4 cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005, 191:1670-1679.
2. Marziali M, De Santis W, Carello R. T-cell homeostasis alteration in HIV-1-infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006, 20:2033-2041.
3. Aiuti F, Mezzaroma I. Failure to reconstitute CD4 T-cells despite suppression of HIV replication under HAART. AIDS Rev 2006, 8:88-97.
4. D'Egidio GE, Kravcik S, Cooper CL, Cameron DW, Fergusson DA, Angel JB. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4 T-cell count <200 cells/microL when viral replication is suppressed. AIDS 2007, 21:1711-1715.
5. Phair J, Muñoz A, Detels R. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990, 322:161-165.
6. Detels R, Phair JP, Saah AJ. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol (Japan) 1992, 2((Suppl)):11-19.
7. Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J. The Multicenter AIDS Cohort Study. Am J Epidemiol 1995, 142:323-330.
8. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study. Am J Epidemiol 1987, 126:310-318.
9. Schenker EL, Hultin LE, Bauer KD, Ferbas J, Margolick JB, Giorgi JV. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry 1993, 14:307-317.
10. Castro KG, Ward JW, Slutsker L. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992, 41:1-19.
11. http://aidsinfo.nih.gov/guidelines/, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents among HIV-infected adults and adolescents. Available at, accessed 27 June 2008)
12. Farel CE, Chaitt DG, Hahn BK. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004, 103:3282-3286.
13. Losso M, Abrams D. and the INSIGHT ESPRIT Study Group., Effect of interleukin-2 on clinical outcomes in patients with CD4 cell count of 300 cells/mm: primary results of the ESPRIT Study. . Montreal, Canada, February 2009 [Abstract 90aLB]
14. Levy Y. SILCAAT Scientific Committee, Effect of interleukin-2 on clinical outcomes in patients with CD4 cell count 50 to 299 cells/mm: primary results of the SILCAAT Study. . Montreal, Canada, February 2009 [Abstract 90bLB]
15. Fätkenheuer G, Nelson M, Lezarrin A. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359:1442-1455.